The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Novo Nordisk continues ... trials for oral semaglutide that are due to complete this year. Semaglutide is already approved for type 2 diabetes in a patient-friendly weekly injection, branded ...

Now that Novo Nordisk A/S’ blockbuster semaglutide franchise has been selected as one drug for the next round of the CMS price negotiation, the Bagsværd, Denmark-based company is asking a U.S.

Novo Nordisk has announced that the Food and Drug Administration ... cardiovascular events in adults also with known heart disease, establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as ...

In May 2024, Novo Nordisk released the full results ... cardiovascular-related mortality from the once-weekly semaglutide 1.0 milligram injection, and an 18% reduced risk of major cardiovascular ...

On the positive side, Novo Nordisk also made headlines with the successful results of its STEP UP trial for Semaglutide 7.2 mg, which demonstrated a significant 20.7% weight loss over 72 weeks ...

Novo Nordisk recently published favorable results from the FLOW renal outcomes trial, which found that Ozempic (semaglutide) 1.0 mg lowered the risk of kidney disease progression and kidney and ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...